University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Docetaxel for the treatment of prostate cancer.

Gilbert, DC and Parker, C (2005) Docetaxel for the treatment of prostate cancer. Future Oncol, 1 (3). pp. 307-314.

Full text not available from this repository.

Abstract

Prostate cancer accounts for 12% of male cancer deaths, amounting to almost 10,000 deaths per year in the UK. Patients that develop metastatic disease may have their prostate cancer controlled for approximately 2 years with androgen deprivation but invariably progress to a castrate-independent state and succumb to metastatic disease. The previous experience of cytotoxic chemotherapy in hormone-refractory prostate cancer has yielded modest improvements in quality of life, with mitoxantrone in widest use. However, following encouraging Phase II data, two Phase III trials have demonstrated a survival advantage associated with the use of the synthetic taxoid cytotoxic docetaxel (Taxotere) over mitoxantrone and prednisolone. Moreover, this treatment was well tolerated. Therefore, docetaxel is set to be the standard by which future interventions are judged and a platform for future trials containing novel molecular therapies.

Item Type: Article
Authors :
NameEmailORCID
Gilbert, DCd.gilbert@surrey.ac.ukUNSPECIFIED
Parker, CUNSPECIFIEDUNSPECIFIED
Date : June 2005
Identification Number : https://doi.org/10.1517/14796694.1.3.307
Uncontrolled Keywords : Antineoplastic Agents, Phytogenic, Drug Resistance, Neoplasm, Humans, Male, Neoplasm Recurrence, Local, Prostatic Neoplasms, Taxoids
Related URLs :
Depositing User : Symplectic Elements
Date Deposited : 16 May 2017 14:52
Last Modified : 17 May 2017 14:28
URI: http://epubs.surrey.ac.uk/id/eprint/815508

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800